Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

LY4268989 · MORF-057

Small molecule · developed by ELI LILLY &

Phase 2 Most advanced trial

LLY Developer

1 Registered trials

What is LY4268989?

LY4268989, also known as MORF-057 and zotemtegrast, is a drug studied in ulcerative colitis, including active moderate and active severe disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MORF-057, zotemtegrast
Drug type: Small molecule
Therapy area: Gastroenterology
Developer: ELI LILLY & (LLY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: UGG5JJ82AH

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07415044	Phase 2	Ulcerative Colitis (UC)	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Follow LLY, the company behind LY4268989

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z